Serotonergic Drugs Inhibit Chikungunya Virus Infection at Different Stages of the Cell Entry Pathway

• Published in: Journal of virology 2020-06, Vol.94 (13)
• Main Authors: Bouma, Ellen M, van de Pol, Denise P I, Sanders, Ilson D, Rodenhuis-Zybert, Izabela A, Smit, Jolanda M
• Format: Article
• Language: English
• Subjects: Animals; Antiviral Agents - pharmacology; Cell Line; Chikungunya Fever - drug therapy; Chikungunya Fever - virology; Chikungunya virus - drug effects; Chikungunya virus - physiology; Chlorocebus aethiops; Humans; Membrane Fusion - drug effects; RNA, Viral - genetics; Serotonin - analogs & derivatives; Serotonin - pharmacology; Serotonin Agents - metabolism; Serotonin Agents - pharmacology; Serotonin Receptor Agonists - pharmacology; Tryptamines - pharmacology; Vero Cells; Virus Attachment - drug effects; Virus Internalization - drug effects; Virus Replication - drug effects; Virus-Cell Interactions
• ISSN: 0022-538X; 1098-5514
• DOI: 10.1128/JVI.00274-20

Chikungunya virus (CHIKV) is an important reemerging human pathogen transmitted by mosquitoes. The virus causes an acute febrile illness, chikungunya fever, which is characterized by headache, rash, and debilitating (poly)arthralgia that can reside for months to years after infection. Currently, effective antiviral therapies and vaccines are lacking. Due to the high morbidity and economic burden in the countries affected by CHIKV, there is a strong need for new strategies to inhibit CHIKV replication. The serotonergic drug 5-nonyloxytryptamine (5-NT) was previously identified as a potential host-directed inhibitor for CHIKV infection. In this study, we determined the mechanism of action by which the serotonin receptor agonist 5-NT controls CHIKV infection. Using time-of-addition and entry bypass assays, we found that 5-NT predominantly inhibits CHIKV in the early phases of the replication cycle, at a step prior to RNA translation and genome replication. Intriguingly, however, no effect was seen during virus-cell binding, internalization, membrane fusion and genomic RNA (gRNA) release into the cell cytosol. In addition, we show that the serotonin receptor antagonist methiothepin mesylate (MM) also has antiviral properties toward CHIKV and specifically interferes with the cell entry process and/or membrane fusion. Taken together, pharmacological targeting of 5-HT receptors may represent a potent way to limit viral spread and disease severity. The rapid spread of mosquito-borne viral diseases in humans puts a huge economic burden on developing countries. For many of these infections, including those caused by chikungunya virus (CHIKV), there are no specific treatment possibilities to alleviate disease symptoms. Understanding the virus-host interactions that are involved in the viral replication cycle is imperative for the rational design of therapeutic strategies. In this study, we discovered an antiviral compound, elucidated its mechanism of action, and propose serotonergic drugs as potential host-directed antivirals for CHIKV.